Allogeneic bone marrow transplantation in myelofibrosis (program ID: 103243)

University Hospital Heidelberg

location_on Heidelberg, Germany
9.8/10 from 57 Votes
Specialized hospital
Carsten Müller-Tidow

Head Physician
Prof. Dr. med.

Carsten Müller-Tidow

Specialized in: hematology, oncology, adult and pediatric rheumatology

Department of Hematology, Oncology, Adult and Pediatric Rheumatology

Program includes:

  • Initial presentation in the clinic
  • case history collection
  • general clinical examination
  • laboratory tests:
    • complete blood count
    • biochemical analysis of blood
    • TSH-basal, fT3, fT4
    • differential blood count
    • inflammation indicators (CRP, ESR)
    • indicators of blood coagulation
  • CT/MRI scans of the whole body
  • needle biopsy of the bone marrow
  • biopsy and histological examination of CSF
  • examination by experts of:
    • cardiology
    • otolaryngology
    • immunology
    • ophthalmology
  • registration in the European bone marrow donor base
  • conducting high-dose chemotherapy
  • allogeneic bone marrow transplantation from
    unrelated donor
  • the cost of blood products
  • isolation by neutropenic precautions
  • symptomatic treatment
  • control examinations
  • the cost of essential medicines and materials
  • nursing services
  • full hospital accommodation
  • explanation of future recommendations

How program is carried out

During the first visit, the doctor will conduct a clinical examination and go through the results of the available diagnostic tests. After that, you will undergo the necessary additional examination, such as the assessment of liver and kidney function, ultrasound scan, CT scan and MRI.

Also, the doctor will conduct a bone marrow biopsy followed by cytological examination of the harvested material. This will help him to determine the histological features of your bone marrow (in particular, identify HLA system antigens) and select a suitable donor. The donor can be a family member or a person from the bone marrow registry. In the second case, the donor material is stored in a bone marrow bank.

Before the procedure, you will receive chemotherapy, if necessary in combination with radiation therapy. The course of chemo- or chemoradiation therapy lasts from 2 to 8 days.

The bone marrow transplant procedure is an intravenous infusion, i.e. the healthy bone marrow will be injected through a catheter, intravenously. You will stay in your room during the procedure. A bone marrow transplant is completely painless and does not require anesthesia.

During the period of healthy bone marrow engraftment, you will stay in a sterile ward. This is a necessary precaution because during this time your immune system is very weak and cannot withstand environmental pathogens. The risk of bleeding is also quite high, so you will be advised to avoid mechanical damage.

A relative or other close person may stay in the ward with you. You will not be allowed to go outside the department and leave your ward often. The rehabilitation period can last from 1 to 2 months.

When your complete blood count returns to normal, your doctor will schedule your discharge from the department. You will receive information about the rules that you will need to follow at home, the frequency and type of control examinations, and subsequent treatment measures. You will also receive a detailed medical report, which will reflect the entire course of treatment.

Required documents

  • Medical records
  • Bone marrow biopsy results (if available)
Type of program :
Expected duration of the program:

You may also book


About the department

The Department of Hematology, Oncology, Adult and Pediatric Rheumatology at the University Hospital Heidelberg offers the full range of modern diagnostics and treatment of malignant diseases, rheumatic pathologies, including particularly complex clinical cases in these fields. In addition, the department's doctors specialize in bone marrow transplantation and occupy leading positions in this field at the international level. The department is headed by Prof. Dr. med. Carsten Müller-Tidow.

The medical team of the department makes every effort to guarantee each patient an individual, first-class treatment, based on the very latest achievements of modern medicine and human respect, understanding of the needs of each patient.

The service range of the department includes:

  • Hematology
    • Bone marrow transplantation
    • Diagnostics and treatment of leukemias
      • Acute lymphocytic leukemia
      • Chronic lymphocytic leukemia
      • Hairy cell leukemia
      • T-prolymphocytic leukemia
    • Diagnostics and treatment of myelodysplastic syndrome
    • Diagnostics and treatment of malignant lymphomas
    • Diagnostics and treatment of myeloproliferative diseases
      • Chronic myeloid leukemia (BCR-ABL1 mutation)
      • Chronic neutrophilic leukemia
      • True polycythemia
      • Primary myelofibrosis (prefibrotic stage, open primary myelofibrosis)
      • Essential thrombocythemia
      • Chronic eosinophilic leukemia
      • Unclassifiable myeloproliferative neoplasia
    • Diagnostics and treatment of multiple myeloma
      • Conventional chemotherapy
      • High-dose chemotherapy 
      • Therapy with the use of new drugs (thalidomide, lenalidomide, bortezomib)
      • Radiation therapy
      • Treatment of complications, as well as maintenance therapy
      • Introduction of new therapeutic approaches according to the results of clinical trials
      • Kyphoplasty
    • Diagnostics and treatment of amyloidosis
      • Classical chemotherapy for the firstly diagnosed disease and relapse
      • High-dose chemotherapy
      • Diagnostics of previously unclassified amyloidosis
      • Second opinion during and after chemotherapy
  • Oncology
    • Diagnostics and treatment of cancer of unknown primary
    • Diagnostics and treatment of malignant germ cell tumors (testicular tumors)
    • Diagnostics and treatment of malignant bone tumors (osteosarcoma, Ewing's sarcoma)
    • Diagnostics and treatment of malignant soft tissue tumors (soft tissue sarcoma)
  • Rheumatology
    • Diagnostics and treatment of rheumatoid arthritis
    • Diagnostics and treatment of spondyloarthritis
    • Diagnostics and treatment of vasculitides
    • Diagnostics and treatment of collagenoses
    • Diagnostics and treatment of autoimmune diseases
    • Diagnostics and treatment of sarcoidosis
    • Diagnostics and treatment of neuromuscular diseases
    • Diagnostics and treatment of inflammatory eye diseases (uveitis)
    • Diagnostics and treatment of rheumatological diseases in children and adolescents
    • Diagnostics and treatment of fibromyalgia (primary and secondary form)
    • Diagnostics and treatment of degenerative changes, crystalline arthropathy
    • Diagnostics and treatment of congenital collagenoses and lysosomal storage diseases
  • Diagnostics and treatment of other hematologic, oncologic and rheumatic diseases

Curriculum vitae

Prof. Dr. med. Carsten Müller-Tidow studied medicine in Aachen, Bonn and the USA. He began his clinical work in Internal Medicine at the University Hospital Muenster and for several years participated in the scholarship program of the German Research Foundation (DFG) in Los Angeles at the University of California (UCLA). After training to become a Medical Specialist in Internal Medicine at the University Hospital Muenster, he became a Fellow of the Heisenberg Foundation of the German Research Foundation.

In 2009, the doctor received the title of a University Professor of Internal Medicine with a focus on Hematology and Oncology, University of Muenster.

From 2014 to 2017, he served as the Head of the Department of Hematology and Oncology and the Head of the Center for Cellular and Gene Therapy at the University Hospital Halle.

Since February 2017, the doctor is the Head of the Department of Hematology, Oncology, Adult and Pediatric Rheumatology at the University Hospital Heidelberg. He is also a Mof the extended presidium of the National Cancer Center (NCT).

The main clinical focuses of Prof. Müller-Tidow cover the treatment of acute leukemia, myelodysplastic syndrome, lymphomas, multiple myeloma. It is important for him not only to adhere to the highest standards in his daily clinical practice, but also to develop new methods of treatment together with the medical team of the department.

The key research focuses are acute myeloid leukemia, epigenetic changes in tumors, stem cell application and genomics. The professor received many awards for his works. 

Photo: (с) depositphotos

About hospital

Accommodation in hospital

There are 33 myelofibrosis treatment hospitals on Booking Health website

Show all clinics


Need Help?

Thank you!

We received your treatment application in the best Europe clinics. Our manager will contact you within the next 24 hours.